Citadel Advisors
BBC icon

Citadel Advisors’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Citadel Advisors’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Buy
42,736
+14,652
+52% +$653K ﹤0.01% 6291
2026
Q1 		$1.17M Sell
28,084
-12,839
-31% -$526K ﹤0.01% 7308
2025
Q4 		$1.58M Buy
+40,923
New +$1.39M ﹤0.01% 6402
2024
Q4 		– Sell
-34,631
Closed -$968K – 14487
2024
Q3 		$968K Sell
34,631
-5,469
-14% -$151K ﹤0.01% 6933
2024
Q2 		$1.01M Buy
+40,100
New +$1.07M ﹤0.01% 6548
2024
Q1 		– Sell
-37,327
Closed -$913K – 14545
2023
Q4 		$913K Buy
37,327
+1,815
+5% +$35.8K ﹤0.01% 6857
2023
Q3 		$697K Buy
35,512
+1,824
+5% +$40.5K ﹤0.01% 7348
2023
Q2 		$807K Buy
33,688
+925
+3% +$22.3K ﹤0.01% 6905
2023
Q1 		$718K Buy
+32,763
New +$824K ﹤0.01% 7501
2021
Q1 		– Sell
-12,801
Closed -$635K – 13150
2020
Q4 		$635K Buy
12,801
+2,083
+19% +$93.6K ﹤0.01% 7700
2020
Q3 		$418K Buy
+10,718
New +$437K ﹤0.01% 7586
2019
Q4 		– Sell
-13,951
Closed -$332K – 9100
2019
Q3 		$332K Buy
13,951
+5,834
+72% +$159K ﹤0.01% 7416
2019
Q2 		$234K Buy
+8,117
New +$227K ﹤0.01% 7960
2018
Q4 		– Sell
-18,447
Closed -$638K – 9089
2018
Q3 		$638K Buy
+18,447
New +$622K ﹤0.01% 6309
2017
Q1 		– Sell
-23,166
Closed -$426K – 7424
2016
Q4 		$426K Buy
+23,166
New +$462K ﹤0.01% 5158
2016
Q3 		– Sell
-16,139
Closed -$291K – 7225
2016
Q2 		$291K Buy
+16,139
New +$316K ﹤0.01% 5256
2016
Q1 		– Sell
-32,531
Closed -$945K – 6773
2015
Q4 		$945K Buy
32,531
+19,928
+158% +$576K ﹤0.01% 3648
2015
Q3 		$333K Buy
+12,603
New +$426K ﹤0.01% 5407

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Citadel Advisors's BBC Position: Q2 2026 in Review

Citadel Advisors increased its Virtus Biotech Clinical Trials ETF (BBC) stake by 52% in Q2 2026, buying an estimated $653K and bringing the position to 42,736 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #6291.

Citadel Advisors first reported a position in BBC in Q3 2015 and has held it in 18 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

  • Citadel Advisors held 42,736 shares of Virtus Biotech Clinical Trials ETF worth $2.25M as of Q2 2026.
  • Citadel Advisors bought 14,652 Virtus Biotech Clinical Trials ETF shares in Q2 2026, an estimated $653K.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6291 holding.
  • Citadel Advisors first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2015 and has held it in 18 quarters since.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.